Skip to main content
OpenTrials
Completed

NCT Number: NCT02000674

Succinylcholine vs Rocuronium for Prehospital Emergency Intubation

All adult patients with spontaneous cardiac activity and requiring tracheal intubation in the pre hospital emergency context will be included in order to compare the use of succinylcholine vs Rocuronium for prehospital emergency intubation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU de La Réunion, Saint-Denis, La Réunion, France

Loading trial locations.

About this study

All adult patients with spontaneous cardiac activity and requiring tracheal intubation in the pre hospital emergency context will be included. All intubation will be performed by an emergency physician or a nurse specialized in anesthesia. For patients with spontaneous cardiac activity, rapid sequence intubation will be performed to allow intubation.

Comparisons studied will be : Intubation success rate at the first laryngoscopy, glottis exposure assessed by Cormack and Lehane classification, difficult intubation rate assessed by the Intubation Difficult Score (IDS), the conditions of intubation assessed by the Copenhagen score, the need for alternative airway techniques and the immediate post intubation complications rate as vomiting, dental trauma, pulmonary inhalation, arterial desaturation , hypotension episodes and cardiac arrest occurrence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All adult patients with spontaneous cardiac activity and requiring tracheal intubation in the pre hospital emergency context

Exclusion criteria

  • Patients in cardiac arrest;
  • Patients under-18s;
  • Patients under guardianship ;
  • Pregnancy known;
  • Patients with cons to one of the following three drugs: rocuronium, succinylcholine, sugammadex;
  • Patients not affiliated to a social security scheme (beneficiary or legal).

Treatment and study plan

Succinylcholine : 1mg/kg

Drug

Other names: Suxaméthonium Aguetant®, SUXAMETHONIUM BIOCODEX 50 mg/ml, solution injectable

Rocuronium : 1.2 mg/kg

Drug

Other names: ESMERON®

Primary outcomes

  1. First-pass intubation success rate

    Time frame: between 1 hour to 3 hours after inclusion

    Measured by the proportion of successful intubation in the first laryngoscopy.

Secondary outcomes

  1. Incidence of difficult intubation

    Time frame: between 1 hour to 3 hours after inclusion

    measured by the Intubation Difficulty Scale

  2. Intubation conditions assessment

    Time frame: between 1 hour to 3 hours after inclusion

    using the Copenhagen score

  3. Need for alternate airway devices

    Time frame: between 1 hour to 3 hours after inclusion

  4. early intubation-related complications

    Time frame: between 1 hour to 3 hours after inclusion

    complications : esophageal intubation, mainstem intubation, vomiting, pulmonary aspiration, dental trauma, bronchospasm or laryngospasm, ventricular tachycardia, arterial desaturation, hypotension, or cardiac arrest

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Other

Collaborators

  • Hôpital Necker-Enfants Malades
  • Unité de Soutien Méthodologique (CHU de La Réunion)

Registry information

Official study title

Succinylcholine vs Rocuronium for Prehospital Emergency Intubation : a Randomized Trial

Acronym: CURASMUR

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Dec 4, 2013
Registry last updated
Dec 15, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.